Piper Sandler Reiterates Overweight Rating on Beta Bionics, Sets $24 Target
Piper Sandler reiterated its Overweight rating and $24 price target on Beta Bionics. The target implies 12.2% upside from the Oct. 27 close of $21.39.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.